Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday September 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Power3 Medical Products Inc. CEO Interview: Helen R. Park

67 WALL STREET, New York - September 15, 2009 - The Wall Street Transcript has just published its Medical Research Services report offering a timely review of the sector to serious investors and industry executives. This 23 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Medical Device Research Services - Pharmaceutical Research Services - Diagnostics - Life Science Research Supplies

...

6Power3 Medical Products Inc. CEO Interview: Helen R. Park7 WALL STREET, New York - September 15, 2009 - The Wall Street Transcript has just published its Medical Research Services report offering a timely review of the sector to serious investors and industry executives. This 23 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Medical Device Research Services - Pharmaceutical Research Services - Diagnostics - Life Science Research Supplies - Biology R & D - Lab Services Business Model - International Economic Exposure - Effect of Recession on Sector Stocks - Top Stock Winners and Losers in Medical Research Services - Top Stock Winners and Losers in Medical Diagnostics

Companies include: Arrowhead Research (ARWR); Cleveland BioLabs (CBLI); IR BioSciences Holdings (IRBS); Power3 Medical Products (PWRM);

...

CRWENewswire.com is pleased to announce a stock highlight on The United Illuminating Company (NYSE:UIL, ICF Incorporated, LLC,(NASDAQ:ICFI),Laboratory Corporation of America® Holdings (NYSE:LH)

The United Illuminating Company (NYSE:UIL) Tuesday August 4, 2009, filed an application with the U.S. Department of Energy (DOE) for a $37.5 million grant in “Smart Grid” funds that would enable the company to accelerate efforts to modernize its transmission and distribution system.

About UIL Holdings Corporation UIL Holdings Corporation engages in the purchase, transmission, distribution, and sale of electricity in the United States

ICF Incorporated, LLC, a subsidiary of ICF International (NASDAQ:ICFI), announced today the award of a new, multi-year contract valued at up to $27 million with the U.S. Department of Agriculture (USDA) Rural Development, Rural Utilities Service (RUS). Under this contract, the ICF team will support the RUS Broadband Initiatives Program, a part of the American Recovery and Reinvestment Act of 2009. About ICF International

ICF International (NASDAQ:ICFI) partners

...

Laboratory Corp. of America Holdings (LH)

Laboratory Corporation of America® Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $4.5 billion in 2008, over 28,000 employees worldwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

Web site at: www.labcorp.com

Recent News:

Laboratory Corporation of America® Holdings (NYSE:LH) today announced the successful completion of its acquisition of Monogram Biosciences, Inc. LabCorp acquired Monogram pursuant to a cash tender offer followed by the merger of a wholly-owned subsidiary of LabCorp with and into Monogram.

 

Senior Housing Properties Trust (SNH)

Senior Housing Properties Trust, a real estate investment trust (REIT), primarily invests in senior housing properties in the United States.

Web Site:

...

On July 17, 2009, South San Francisco-based life science company Monogram Biosciences, Inc. (MGRM) and North Carolina-based clinical laboratory company Laboratory Corp. of America Holdings (LH) announced that the proposed acquisition of the former is well on its way since the waiting period under Hart-Scott-Rodino has expired with neither the Federal Trade Commission nor the U.S. Department of Justice acting.   The acquisition of Monogram by LabCorp was announced in June this year for about $106.7 million in cash. In addition, LabCorp had agreed to assume about $48 million in debt. With an eye on the acquisition, the clinical laboratory company initiated a tender offer on July 1, 2009 for all of the outstanding shares of common stock of Monogram for $4.55 per share in cash. The offer is scheduled to expire on July 29 unless otherwise extended.   The transaction, which is expected to close in ...

Late last month, life sciences company Monogram Biosciences (MGRM) announced that it will be acquired by clinical laboratory firm Laboratory Corp. of America Holdings (LH) for $106.7 million, or a total enterprise value of approximately $155 million at the end of March 31. The acquisition is expected to close in the third quarter of 2009.

As per terms of the agreement, LabCorp's acquisition subsidiary Mastiff Acquisition Corp. has commenced a tender offer to purchase all outstanding shares of Monogram Biosciences for $4.55 per share in cash, without interest. Following completion of the tender offer, Mastiff and Monogram are expected to merge. The non-purchased shares will be converted into rights to receive equivalent cash value as in the tender offer.

Monogram is committed to advancing personalized medicine and improving patient outcomes through the development of innovative products that guide and target the most appropriate treatments. We are optimistic

...

For Immediate Release

Chicago, IL - June 24, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: LabCorp (LH), Monogram Biosciences, Inc. (MGRM), Pfizer (PFE), Quest Diagnostics (DGX) and Myriad Genetics (MYGN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday's Analyst Blog:

Monogram Acquired by LabCorp

LabCorp (LH) and Monogram Biosciences, Inc. (MGRM) announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55

...

Below are 12 extreme FDA trades for 11 companies with market caps below $200M which have pending new drug product decisions or other meetings/milestones scheduled with the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced. A high risk/reward trading approach to consider for speculative traders is investing a small amount of money that you can afford to lose in a basket of stocks included in extreme FDA and Clinical Trial Calendar trades, which are highlighted in periodic articles at BioMedReports.com.

Hemispherx Biopharma [HEB: 1.36, -0.10 (-6.85%)]: Ampligen (Poly I: Poly C12U) NDA (three month PDUFA decision date delay was announced on 2/18/09 as additional data was submitted by HEB within three months of original decision date). Ampligen is an experimental treatment for chronic fatigue syndrome (which has no

...

ARCA Biopharma, Inc.

(Public, NASDAQ:ABIO)

Heart failure has always been one of the predominant fatal human conditions, therefore this week I will be focusing on a company which has developed a highly successful treatment.

The broad world market for this drug is truly spectacular.

Key Facts: Heart failure becomes more common with increasing age. About 1 in 35 people aged 65-74 years have heart failure. This increases to about 1 in 15 of people aged 75-84 years, and to just over 1 in 7 people aged 85 years and above. It is uncommon in younger people.

It is difficult to give an outlook (prognosis) for an individual. In general, the more severe the heart failure, the worse the outlook. In many cases, the symptoms remain at a stable level for quite some time (months or years) before becomming worse. In some cases the severity

...

Shares of Vanda Pharma [VNDA: 7.87, +6.79 (+628.70%)] soared by nearly nine-fold in after-hours trading Wednesday evening as Fanapt (iloperidone) was approved by the FDA for the acute treatment of adult patients with schizophrenia. The approval was supported by two placebo-controlled Phase 3 clinical studies comparing Fanapt to placebo and active control in patients with schizophrenia, as well as safety data in more than 3,000 patients.

Below are the nine remaining companies from my article last month on a dozen extreme FDA trades of companies with market caps below $200M which have pending new drug product decisions at the FDA that are expected to have a major impact on each of the underlying stock prices as the PDUFA decision dates approach and the decision is ultimately announced.

1.) Vion Pharma [VION: 0.00, N/A (N/A)]: Onrigin (laromustine) Injection (formerly known as Cloretazine or VNP40101M) NDA requesting approval as

...